secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001493152-26-002428
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K
--------------------------------------------------------------------------------

- Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
- Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.
- Annual cash bonus target 35% of base salary based on Board-set goals.
- Change-of-control bonus: 3% of enterprise value if ≥$5M.
- Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/0001493152-26-002428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer